David A. Siegel Synthetic Biologics, Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.9 - $2.9 $9,310 - $14,210	-4,900 Reduced 3.5%	135,300 $29,000
Q1 2022 May 16, 2022	SELL	$2.3 - $4.3 $55,889 - $104,490	-24,300 Reduced 14.77%	140,200 $40,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.5 $97,740 - $162,900	36,200 Added 28.22%	164,500 $45,000
Q3 2021 Nov 15, 2021	BUY	$4.3 - $5.8 $406,780 - $548,680	94,600 Added 280.71%	128,300 $59,000
Q2 2021 Aug 16, 2021	BUY	$4.6 - $7.2 $155,020 - $242,640	33,700 New	33,700 $20,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.